[Antithrombotics in the management of thrombotic antiphospholipid syndrome]

The thrombotic antiphospholipid syndrome is defined by persistent antiphospholipid antibodies and vascular thrombosis. Recommendations for the secondary thrombotic prevention in the thrombotic antiphospholipid syndrome are weak, based on a low-to-moderate quality of evidence. When the initial event leading to diagnosis is a venous thrombosis, the prevention of recurrence of a thrombotic event is based on anticoagulation with a vitamin K antagonist. When the initial event is an arterial thrombosis, the optimal antithrombotic regimen is more controversial and the role of aspirin is debated. Recent data suggest not to use direct oral anticoagulant in the -setting of the thrombotic antiphospholipid syndrome. The identification of patients with low risk of thrombotic recurrence could help in tailoring antithrombotic therapy.